HerbertLancashireDupontMD

Infectious Disease • Houston, TX

Clinical Professor, Infectious Disease, Baylor College of Medicine

Join to view full profile

Dr. Dupont is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Dupont's full profile

Already have an account?

Office
1200 Hermann Pressler Dr
Houston, TX 77030
Is this information wrong?

Education & Training

University of MarylandFellowship, Infectious Disease, 1968 - 1969
University of MinnesotaResidency, Internal Medicine, 1965 - 1967
Emory University School of MedicineClass of 1965

Certifications & Licensure

TX State Medical License 1973 - 2024
GA State Medical License 1965 - 1987
American Board of Internal Medicine Internal Medicine

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly, 2002-2014
Top Doctors:SE Texas Castle Connolly, 2013
Elected Member The American Society for Clinical Investigation, 1980
Super Doctor SuperDoctors.com
Top MD Consumers Checkbook
Join now to see all

Clinical Trials

Rifaximin, Loperamide and the Combination to Treat Travelers' Diarrhea Start of enrollment: 2004 Jun 01
Completed
Phase 4
Compassionate Use of Nitazoxanide for the Treatment of Clostridium Difficile Infection Start of enrollment: 2004 Jan 01
Completed
Phase 3
Study of the Clinical Effectiveness of a Human Monoclonal Antibody to C. Difficile Toxin A and Toxin B in Patients With Clostridium Difficile Associated Disease Start of enrollment: 2006 Jul 20
Completed
Phase 2
Safety and Efficacy of Prulifloxacin Versus Placebo in Traveler's Diarrhea Start of enrollment: 2006 Aug 01
Completed
Phase 3
Study of Nitazoxanide in the Treatment of Clostridium Difficile Colitis Start of enrollment: 2004 Jan 01
Completed
Phase 2
ETEC Logistics Trial (TREK) Start of enrollment: 2006 May 01
Completed
Phase 2
Study to Determine the Best Way to Measure How Quickly the Drug Can Give Relief From Sudden Diarrhea Start of enrollment: 2008 Oct 01
Completed
Phase 4
Travelers' Diarrhea (TD) Vaccine Pivotal Efficacy Study Start of enrollment: 2009 Oct 01
Completed
Phase 3
SER-109 Versus Placebo to Prevent Recurrent Clostridium Difficile Infection (RCDI) Start of enrollment: 2015 May 01
Completed
Phase 2
Characterization of Fecal Microbiome Changes After Administration of PRIM-DJ2727 in Parkinson's Disease Patients Start of enrollment: 2017 Jul 15
Withdrawn
Phase 1, Phase 2
Dose Ranging Study of the Safety and Efficacy of Orally Administered Lyophilized Fecal Microbiota Product (PRIM-DJ2727) for the Treatment of Recurrent Clostridium Difficile Infection (CDI) Start of enrollment: 2017 Dec 21
Terminated
Phase 2
Study of the Fecal Microbiome in Patients With Parkinson's Disease Start of enrollment: 2019 May 15
Completed
Phase 1
Fecal Microbiota Transplantation (FMT): PRIM-DJ2727
Available
A Prospective, Randomized, Placebo-Controlled Pilot Study to Characterize the Intestinal Microbiome and to Evaluate the Safety and Fecal Microbiome Changes Following Administration of Lyophilized PRIM-DJ2727 or Placebo Given Orally in Subjects With Nonalcoholic Fatty Liver Disease Start of enrollment: 2023 Dec 01
Not yet recruiting
Phase 2
Roles: Principal Investigator, Contact
Evaluation the Safety and Efficacy of Lyophilized Fecal Microbiota Transplantation Administered Orally for Prevention of Relapse or Intestinal Inflammation in Adults With Ulcerative Colitis Start of enrollment: 2020 Sep 14
Recruiting
Phase 2
Roles: Contact, Principal Investigator
Study to Evaluate the Fecal Microbiota Transplantation (FMT) in the Treatment of Ulcerative Colitis Start of enrollment: 2023 Dec 15
Not yet recruiting
Phase 1
Roles: Principal Investigator, Contact
Join now to see all

Publications & Presentations

PubMed

9 citations
Microbiome alteration via fecal microbiota transplantation is effective for refractory immune checkpoint inhibitor-induced colitis.
Taylor M Halsey, Anusha S Thomas, Tomo Hayase, Weijie Ma, Hamzah Abu-Sbeih, Baohua Sun, Edwin Roger Parra, Zhi-Dong Jiang, Herbert L DuPont, Christopher Sanchez, Rawan...> ;Science Translational Medicine. 2023 Jun 14
1 citations
IgA-Biome Profiles Correlate with Clinical Parkinson's Disease Subtypes.
Eric L Brown, Heather T Essigmann, Kristi L Hoffman, Ashley S Alexander, Michael Newmark, Zhi-Dong Jiang, Jessika Suescun, Mya C Schiess, Craig L Hanis, Herbert L DuPont> ;Journal of Parkinson's Disease. 2023 Jan 1
3 citations
Intestinal IgA-Coated Bacteria in Healthy- and Altered-Microbiomes (Dysbiosis) and Predictive Value in Successful Fecal Microbiota Transplantation.
Herbert L DuPont, Zhi-Dong Jiang, Ashley S Alexander, Andrew W DuPont, Eric L Brown> ;Microorganisms. 2022 Dec 29
3 citations
A Case of Successful Treatment of Recurrent Urinary Tract Infection by Extended-Spectrum β-Lactamase ProducingUsing Oral Lyophilized Fecal Microbiota Transplant.
Naomi Bier, Blake Hanson, Zhi-Dong Jiang, Herbert L DuPont, Cesar A Arias, William R Miller> ;Microbial Drug Resistance. 2023 Jan 1
Reply to Lutgring et al.
Charles Darkoh, Herbert L DuPont, Cesar A Arias, Micah Oyaro, Eric L Brown, Blake M Hanson> ;Clinical Infectious Diseases. 2022 Oct 29
36 citations
Durable reduction of Clostridioides difficile infection recurrence and microbiome restoration after treatment with RBX2660: results from an open-label phase 2 clinical...
Robert Orenstein, Erik R Dubberke, Sahil Khanna, Christine H Lee, David Yoho, Stuart Johnson, Gail Hecht, Herbert L DuPont, Dale N Gerding, Ken F Blount, Sarah Mische,...> ;BMC Infectious Diseases. 2022 Mar 12
2 citations
Emergence of Clinical Clostridioides difficile Isolates With Decreased Susceptibility to Vancomycin.
Charles Darkoh, Kadiatou Keita, Chioma Odo, Micah Oyaro, Eric L Brown, Cesar A Arias, Blake M Hanson, Herbert L DuPont> ;Clinical Infectious Diseases. 2022 Jan 7
4 citations
The impact of the Th17:Treg axis on the IgA-Biome across the glycemic spectrum.
Heather T. Essigmann, Kristi L. Hoffman, Joseph F. Petrosino, Goo Jun, David Aguilar, Craig L. Hanis, Herbert L. DuPont, Eric L. Brown> ;Plos One. 2021 Oct 20
12 citations
Potential role of probiotics in reducing Clostridioides difficile virulence: Interference with quorum sensing systems.
Sathursha Gunaratnam, Mathieu Millette, Lynne V. McFarland, Herbert L. DuPont, Monique Lacroix> ;Microbial Pathogenesis. 2021 Feb 18
Corrigendum to: Renal Impairment,Recurrence, and the Differential Effect of Bezlotoxumab: A Post Hoc Analysis of Pooled Data From 2 Randomized Clinical Trials.
Yoav Golan, Herbert L DuPont, Fernando Aldomiro, Erin H Jensen, Mary E Hanson, Mary Beth Dorr> ;Open Forum Infectious Diseases. 2021 Jan 1
6 citations
Safety and efficacy of fecal microbiota transplantation to treat and prevent recurrent Clostridioides difficile in cancer patients.
Hiba Ali, Shruti Khurana, Weijie Ma, Yuanzun Peng, Zhi-Dong Jiang, Herbert L. DuPont, Hao Chi Zhang, Anusha Shirwaikar Thomas, Pablo C. Okhuysen, Yinghong Wang> ;Journal of Cancer. 2021 Jan 1
6 citations
Evaluation of Six Weekly Oral Fecal Microbiota Transplants in People with HIV.
Netanya S. Utay, Ana N. Monczor, Anoma Somasunderam, Sofia Lupo, Zhi-Dong Jiang, Ashley S. Alexander, Malcolm Finkelman, Karen J. Vigil, Jordan E. Lake, Blake Hanson, ...> ;Pathogens & Immunity. 2020 Dec 30
3 citations
Approach to the patient with infectious colitis: clinical features, work-up and treatment.
Tehseen Iqbal, Herbert L. DuPont> ;Current Opinion in Gastroenterology. 2021 Jan 1
9 citations
Impact of Diabetes on the Gut and Salivary IgA Microbiomes.
Eric L. Brown, Heather T. Essigmann, Kristi L. Hoffman, Noah W. Palm, Sarah M. Gunter, Joel M. Sederstrom, Joseph F. Petrosino, Goo Jun, David Aguilar, William B. Perk...> ;Infection and Immunity. 2020 Nov 16
Renal Impairment,Recurrence, and the Differential Effect of Bezlotoxumab: A Post Hoc Analysis of Pooled Data From 2 Randomized Clinical Trials.
Yoav Golan, Herbert L DuPont, Fernando Aldomiro, Erin H Jensen, Mary E Hanson, Mary Beth Dorr> ;Open Forum Infectious Diseases. 2020 Jul 1
15 citations
Abnormal Intestinal Microbiome in Medical Disorders and Potential Reversibility by Fecal Microbiota Transplantation.
Herbert L. DuPont, Zhi-Dong Jiang, Andrew W. Dupont, Netanya S. Utay> ;Digestive Diseases and Sciences. 2020 Mar 1
17 citations
Mechanism of action and therapeutic benefit of rifaximin in patients with irritable bowel syndrome: a narrative review.
William D. Chey, Eric D. Shah, Herbert L. DuPont> ;Therapeutic Advances in Gastroenterology. 2020 Jan 23
22 citations
THE INTESTINAL MICROBIOME IN HUMAN HEALTH AND DISEASE.
Herbert L. DuPont, Zhi-Dong Jiang, Andrew W. Dupont, Netanya S. Utay> ;Transactions of the American Clinical and Climatological Association. 2020 Jan 1
9 citations
Activity of Hospital Disinfectants against Vegetative Cells and Spores of Clostridioides difficile Embedded in Biofilms.
Tasnuva Rashid, Farnoosh Haghighi, Irtiza Hasan, Eugénie Bassères, M. Jahangir Alam, Shreela V. Sharma, Dejian Lai, Herbert L. DuPont, Kevin W. Garey> ;Antimicrobial Agents and Chemotherapy. 2019 Dec 20
48 citations
Clostridium difficile Modulates the Gut Microbiota by Inducing the Production of Indole, an Interkingdom Signaling and Antimicrobial Molecule.
Charles Darkoh, Kimberly Plants-Paris, Dayna Bishoff, Herbert L. DuPont> ;Msystems. 2019 Mar 19
3 citations
Rifamycin SV-MMX® as the recommended self-treatment for moderate to severe travellers' diarrhoea: reply.
Robert Steffen, Herbert L. DuPont> ;Journal of Travel Medicine. 2019 May 10
6 citations
Occurrence of putative virulence-related genes, aatA, aggR and aaiC, of Enteroaggregative Escherichia coli (EAEC) among adults with travelers' diarrhea acquired in Gua...
Oluwatosin Bamidele, Zhi-Dong Jiang, Herbert L. DuPont> ;Microbial Pathogenesis. 2019 Mar 1
11 citations
Fecal calprotectin and fecal indole predict outcome of fecal microbiota transplantation in subjects with recurrent Clostridium difficile infection.
J. Hibbard, Zhi-Dong Jiang, Herbert L. DuPont> ;Anaerobe. 2019 Apr 1
11 citations
Author Correction: Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis
Yinghong Wang, Diana H. Wiesnoski, Beth A. Helmink, Vancheswaran Gopalakrishnan, Kati Choi, Hebert L. DuPont, Zhi-Dong Jiang, Hamzah Abu-Sbeih, Christopher A. Sanchez,...> ;Nature Medicine. 2019 Jan 1
3 citations
Estimating the incidence of norovirus acute gastroenteritis among US and European international travelers to areas of moderate to high risk of traveler's diarrhea: a p...
Lisa Lindsay, Herbert L. DuPont, Christine L. Moe, Martin Alberer, Christoph Hatz, Amy E. Kirby, Henry M. Wu, Thomas Verstraeten, Robert Steffen> ;BMC Infectious Diseases. 2018 Dec 3
Join now to see all

Lectures

American College of Physicians: Delaware Chapter 14th Annual Lower Shores Symposia
American College of Physicians, Rehoboth Beach, Delaware - 10/27/2012

Press Mentions

Houstonians Honor Health Heroes and Raise $450,000 for Game-Changing Medical ResearchOctober 23rd, 2018
Avoid Foodborne Illness This Holiday Season with Tips from UTHealth ExpertsNovember 9th, 2017
‘Pill’ on Horizon for Treating Recurrent C Difficile InfectionMarch 14th, 2017
Join now to see all

Grant Support

Infectivity Of Cryptosporidium Parvum For Adult HumansNational Center For Research Resources1994–1997
Study Of The Pathogenesis Of Aeromonas Hydrophila Enteroadherent E. Coli In ManNational Center For Research Resources1985